ICM
CSTL icon

Invenomic Capital Management’s Castle Biosciences CSTL Stock Holding History

Invenomic Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-166,714
Closed -$3.69M – 168
2024
Q1 		$3.69M Sell
166,714
-5,098
-3% -$111K 0.2% 110
2023
Q4 		$3.71M Sell
171,812
-114,145
-40% -$2.01M 0.17% 121
2023
Q3 		$4.83M Buy
285,957
+7,139
+3% +$125K 0.2% 96
2023
Q2 		$3.83M Buy
278,818
+191,566
+220% +$3.88M 0.19% 94
2023
Q1 		$1.98M Buy
+87,252
New +$2.13M 0.11% 124

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invenomic Capital Management's CSTL Position: Q2 2024 in Review

Invenomic Capital Management sold out of Castle Biosciences (CSTL) in Q2 2024, closing a stake of 166,714 shares — an estimated $3.69M sold.

Invenomic Capital Management first reported a position in CSTL in Q1 2023 and held it in 5 quarters. The position peaked at $4.83M in Q3 2023. 159 funds tracked by Wall St. Rank hold CSTL as of Q2 2024.

  • Invenomic Capital Management reported no remaining Castle Biosciences position as of Q2 2024 after selling out during the quarter.
  • Invenomic Capital Management sold 166,714 Castle Biosciences shares in Q2 2024, an estimated $3.69M.
  • Invenomic Capital Management first reported a position in Castle Biosciences in Q1 2023 and held it in 5 quarters.
  • Invenomic Capital Management's Castle Biosciences position peaked at $4.83M in Q3 2023.
  • 159 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2024.

Based on Invenomic Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.